The cost of dasatinib, marketed as Sprycel, can vary significantly depending on factors such as dosage, quantity, insurance coverage, and pharmacy. Without insurance, a 30-day supply of 100 mg dasatinib tablets can range from approximately $8,000 to over $10,000 [1].
What affects the price of Sprycel (dasatinib)?
The price of Sprycel is influenced by several elements. Insurance plans often have co-pays that are much lower than the list price, and patient assistance programs may also be available to help reduce out-of-pocket expenses [1]. The specific formulation and strength of the dasatinib prescription also contribute to the overall cost.
How can I find lower prices for dasatinib?
Patients may find lower prices for dasatinib through various avenues. Comparing prices across different pharmacies can reveal savings. Additionally, patient assistance programs offered by the manufacturer or independent organizations may provide financial support. Prescription discount cards and coupons can also offer reduced costs [1].
When does the patent for dasatinib expire?
The primary patents protecting dasatinib (Sprycel) have faced numerous challenges and some have expired or are nearing expiration. For instance, U.S. Patent No. 7,587,734, originally set to expire in 2027, has been the subject of patent litigation [2]. Information regarding the specific expiration dates of all relevant patents for dasatinib can be found on DrugPatentWatch.com [3].
Are there generic versions of dasatinib available?
The availability of generic versions of dasatinib is linked to patent expirations and successful patent challenges. As patents expire or are invalidated, generic manufacturers can seek approval from regulatory bodies to market their own versions of the drug. The market for generic dasatinib is developing as patent protections diminish [3].
Who are the main competitors to dasatinib?
Dasatinib is used to treat certain types of leukemia, primarily chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its main competitors in this therapeutic area include other tyrosine kinase inhibitors (TKIs) such as imatinib (Gleevec), nilotinib (Tasigna), and bosutinib (Bosulif) [4].
What clinical data supports the use of dasatinib?
Clinical trials have demonstrated dasatinib's efficacy in treating CML and Ph+ ALL. Studies have shown its effectiveness in achieving hematologic, cytogenetic, and molecular responses in patients with newly diagnosed CML, as well as those resistant or intolerant to prior therapies [5][6]. Further clinical data can be found through medical databases and research publications.
Sources:
[1] https://www.goodrx.com/sprycel
[2] https://www.law360.com/articles/1499602/bristol-myers-wins-brl-of-dasatinib-patent-challenge-in-del-
[3] https://www.drugpatentwatch.com/
[4] https://www.cancer.gov/drug-types/tkis
[5] https://ascopubs.org/doi/full/10.1200/JCO.2011.37.5513
[6] https://www.nejm.org/doi/full/10.1056/NEJMoa063152